Catalyst Pharmaceuticals Celebrates Major Achievement in 2025
Catalyst Pharmaceuticals Celebrates Significant Forbes Achievement
Based in Coral Gables, Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) proudly announced its remarkable ranking on Forbes’ prestigious list of America’s Most Successful Mid-Cap Companies for 2025. This is an impressive acknowledgment, with the company securing the fifth position from a competitive pool of 100 mid-cap companies.
Recognition of Sustained Growth and Innovation
Building on last year’s success, where Catalyst was hailed as the fourth in the category of America’s Most Successful Small-Cap Companies, it is clear that the company is on an upward trajectory in its growth journey. The Forbes ranking evaluates crucial metrics such as earnings growth, sales growth, return on equity, and total stock return while placing a stronger emphasis on recent data. This rigorous analysis of performance covered data up to the end of November of the previous year.
Leadership's Insight on the Achievement
Rich Daly, the President and Chief Executive Officer of Catalyst Pharmaceuticals, expressed pride in the company’s achievements, stating, “This ranking is not just a number; it highlights our unwavering commitment to our growth and investment strategies. Our dedicated team strives each day to enhance the lives of patients, and we remain focused on driving value for our patients, employees, and shareholders.”
Forbes Ranking Methodology Explained
The process undertaken by Forbes in compiling this esteemed list involved meticulous criteria. They sifted through a list of over 700 eligible companies, each valued between $2 billion and $10 billion, ensuring these entities experienced positive sales growth in the past year. Companies outside of this financial range, including financial institutions, REITs, utilities, and limited partnerships, were not considered, and neither were those with less than one year in the public market.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is dedicated to catering to patients confronting rare diseases. The firm has a solid history of delivering life-altering therapies to the market. Its approach emphasizes in-licensing and commercializing innovative treatments, all while maintaining a patient-centric strategy. Catalyst stands out for its commitment to accessibility, striving to make sure patients have seamless access to essential care and consistent support throughout their healthcare journey.
Continued Expansion Efforts
Catalyst is not only firmly established in the United States but is also on a quest to broaden its international reach through strategic partnerships that facilitate global growth. The company has recently been recognized for its rapid growth, particularly noted on the 2024 Deloitte Technology Fast 500™ List, which celebrates companies leading in innovation and growth.
Contact Information
For further inquiries or information about Catalyst Pharmaceuticals, individuals are encouraged to consider contacting the company directly. More details and resources are also made available through their official website www.catalystpharma.com.
Frequently Asked Questions
What is Catalyst Pharmaceuticals known for?
Catalyst Pharmaceuticals specializes in developing biopharmaceutical treatments for rare diseases, focusing on innovative therapies and patient care.
What recognition has Catalyst received recently?
Recently, Catalyst Pharmaceuticals ranked fifth in Forbes’ 2025 list of America's Most Successful Mid-Cap Companies, highlighting its continued growth and success.
How does Forbes determine its rankings?
Forbes' rankings are based on several factors including earnings growth, sales growth, return on equity, and total stock return over the most recent five years.
Where is Catalyst Pharmaceuticals headquartered?
The company is headquartered in Coral Gables, Florida, and maintains a strong presence in the U.S. biopharmaceutical sector.
What are Catalyst’s goals moving forward?
Catalyst aims to expand its global footprint while continuing to innovate and provide comprehensive care for patients with rare diseases.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. If any of the material offered here is inaccurate, please contact us for corrections.
